Keytruda (pembrolizumab; Merck & Co) Drug Analysis 2016-2025 - ResearchAndMarkets.com

DUBLIN--()--The "Drug analysis: Keytruda" drug pipelines has been added to ResearchAndMarkets.com's offering.

Keytruda (pembrolizumab; Merck & Co) is a humanized monoclonal antibody designed to inhibit the programmed death-1 (PD-1) co-inhibitory receptor.

The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival and induces apoptosis of tumor-specific T cells. The disruption of this interaction reduces the ability of the tumor to evade immune system targeting and enhances antitumor immune responses.

It has also been hypothesized that blocking the PD-1/PD-L1 interactions releases the cytotoxic function of tumor-specific T cells with fewer toxic effects than those seen with other immune checkpoint inhibitors.

Key Topics Covered:

Product Profiles

  1. Colorectal cancer (CRC)
  2. Head and neck cancer
  3. Hepatocellular carcinoma (HCC)
  4. Bladder cancer
  5. Renal cell cancer (RCC)
  6. Non-small cell lung cancer (NSCLC)
  7. NHL: Diffuse large B-cell lymphoma (DLBCL)
  8. Gastric cancer
  9. Breast cancer: triple-negative
  10. Melanoma
  11. Multiple myeloma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hjj8x8/keytruda?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Skin Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Skin Cancer Drugs